PhoreMost Ltd., the UK-based biopharmaceutical firm devoted to ‘Drugging the Undruggable®’ illness targets, and ThinkCyte Okay.Okay, a biotechnology firm pioneering novel cell evaluation and sorting devices, at the moment introduced a strategic analysis partnership geared toward advancing trendy phenotypic drug screening utilizing synthetic intelligence (AI). The partnership leverages each firms’ distinctive applied sciences in high-throughput drug discovery, PhoreMost’s next-generation phenotypic screening platform, SITESEEKER®, and ThinkCyte’s AI-driven cell characterization and sorting platform, Ghost Cytometry®, with the goal of creating differentiated therapies for a spread of illnesses with unmet scientific want.

Pushed by advances in cell-based phenotypic screening instruments and novel goal discovery applied sciences, the facility of Phenotypic Drug Discovery (PDD) lies in its unmatched means to search out utterly new drug targets and illness mechanisms, offering not solely new drug candidates, however a greater understanding of illness. PhoreMost’s SITESEEKER platform, based mostly on the Firm’s core proprietary ‘Protein Interference’ (PROTEINi) know-how, probes all the proteome to systematically unmask new and unanticipated druggable websites, straight linking them to helpful therapeutic capabilities.

ThinkCyte has pioneered Ghost Cytometry, an strategy that permits detection of novel, disease-related phenotypes. By combining SITESEEKER to determine novel druggable targets with Ghost Cytometry to determine delicate phenotypic modifications in residing cells, the partnership goals to develop a wholly distinctive strategy to high-content phenotypic screening. The analysis partnership will drive ThinkCyte deeper into the sector of early drug discovery and can contribute to PhoreMost’s mission of ‘Drugging the Undruggable®’.

PhoreMost has embraced the revolution in computational strategies to rework the best way we strategy trendy drug discovery,” mentioned Dr. Benedict Cross, CTO of PhoreMost. “By combining ThinkCyte’s AI-based platform to detect novel, disease-related phenotypes with our SITESEEKER phenotypic screening platform, we hope to extra effectively uncover a broad vary of novel targets and translate them into high-quality first-in-class therapeutic property”

We’re very excited concerning the analysis partnership with PhoreMost, a frontrunner in making use of modern approaches and applied sciences to open up new druggable areas.” mentioned Waichiro Katsuda, CEO at ThinkCyte. “We’ve got been privileged to work with drug discovery trade companions who share our imaginative and prescient of utilizing AI to rethink conventional approaches in R&D and stay up for working along with PhoreMost to advance our applied sciences in the direction of the shared aim of constructing significant impression for individuals affected by severe illnesses.”

Source link